Baoji Pharmaceutical

Bao Pharma operates as a biopharmaceutical research, development, and manufacturing enterprise. The company's business model integrates drug development, clinical trial services, and manufacturing, with revenue generated from the production and sale of its therapeutic products. Its clientele consists of patients and healthcare providers across various medical fields, including oncology, autoimmune diseases, rare diseases, and organ transplantation. The company has established a cGMP-compliant manufacturing base in Shanghai designed for multiple drug substance production lines using both mammalian cell and microbial expression systems. This facility is equipped to produce injectable solutions, lyophilized powders, and pre-filled syringes.

The company’s product pipeline targets a range of conditions with significant unmet medical needs. One key product is a recombinant IgG Cleaving Enzyme for treating pathogenic IgG-mediated immune system diseases, which has completed Phase I clinical trials in New Zealand and China. Bao Pharma is also developing a Recombinant Chymotrypsin using genetic engineering to replace traditional animal-derived extraction methods, offering improved safety and quality for applications in numerous medical departments like respiratory medicine and surgery. Another core area is subcutaneous drug delivery, leveraging its expertise in hyaluronidase technology to enhance the administration of therapeutics. Additionally, the company is advancing KJ015, an anti-HER2 bispecific antibody for various solid tumors, and a recombinant human follicle-stimulating hormone (FSH) fusion protein for assisted reproduction, for which a New Drug Application was submitted in December 2023. Keywords: biopharmaceutical, recombinant protein drugs, antibody drugs, drug development, cGMP manufacturing, autoimmune diseases, oncology, assisted reproduction, subcutaneous delivery, recombinant enzymes, monoclonal antibodies, IgG cleaving enzyme, chymotrypsin, hyaluronidase, bispecific antibody, glycoprotein drugs, clinical trials, Series B, Oriental Fortune Capital